



## OpGen to Present Antibiotic Resistance Prediction Data at 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

April 13, 2017

GAITHERSBURG, Md., April 13, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that five posters featuring its technologies will be presented at the 27<sup>th</sup> European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being held April 22-25, 2017 in Vienna, Austria. Among them will be a poster presentation titled "Prediction of antibiotic resistance in *Escherichia Coli* from resistance genes" by Dr. Terry Walker, Senior Vice President of Research and Development at OpGen. The presentation will highlight preliminary results supporting OpGen's efforts to develop and commercialize a rapid and highly accurate test that predicts antibiotic resistance using resistance gene detection and the bioinformatics capabilities of the Acuitas Lighthouse® Knowledgebase. The OpGen booth location is 32B.

The details for the presentations at ECCMID are as follows:

**Poster title:** Prediction of antibiotic resistance in *Escherichia coli* from resistance genes

**Presenter:** T. Walker, OpGen

**Date and time:** Tuesday, April 25 from 12:54 - 12:59 pm CEST

**Location:** Poster Area

**Poster number:** #EP0938

**Abstract number:** #4182

**Session info:** Direct detection methods

**Poster title:** Use of the Acuitas Resistome Test to detect and type carbapenemase producing organisms (CPOs): A pilot study

**Presenter:** G. Vanstone, Royal Free London NHS Foundation Trust

**Date and time:** Saturday, April 22 from 3:30 - 4:30 pm CEST

**Location:** Poster Area

**Poster number:** #P0387

**Abstract number:** #6205

**Session info:** Detection of resistant pathogens

**Poster title:** Rapid outbreak detection of multi-drug resistant organisms using resistance genes profiles

**Presenter:** W. Chang, OpGen

**Date and time:** Saturday, April 22 from 8:45 am - 3:30 pm CEST

**Location:** Poster Area

**Poster number:** #EV0483

**Abstract number:** #5396

**Session info:** Resistance surveillance & epidemiology: Gram-negatives

**Poster title:** Evaluation of QuickFISH and the Sepsityper assays for early identification of aetiological agents in bloodstream infection in a clinical routine setting

**Presenter:** A. Pernestig, Systems Biology Research Centre, University of Skövde

**Date and time:** Monday, April 24 from 1:30 - 2:30 pm CEST

**Location:** Poster Area

**Poster number:** #P1561

**Abstract number:** #1166

**Session info:** Diagnostic microbiology

**Poster title:** Seven years of clinical experience with the Yeast Traffic Light PNA FISH: assay performance and implications on antifungal therapy

**Presenter:** V. Özenci, Karolinska University Hospital

**Date and time:** Sunday, April 23 from 1:30 - 2:30 pm CEST

**Location:** Poster Area

**Poster number:** #P0969

**Abstract number:** #5533

**Session info:** Diagnostic mycology I

### About OpGen

OpGen, Inc. is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital and network-wide infection prevention and treatment. Learn more at [www.opgen.com](http://www.opgen.com) and follow OpGen on Twitter and LinkedIn.

OpGen Contact:

Michael Farmer

Director, Marketing

240-813-1284

[mfarmer@opgen.com](mailto:mfarmer@opgen.com)

[InvestorRelations@opgen.com](mailto:InvestorRelations@opgen.com)

OpGen Investor and Media Contact:  
MacDougall Biomedical Communications  
Cammy Duong  
781-591-3443  
[cduong@macbiocom.com](mailto:cduong@macbiocom.com)



OpGen, Inc.